Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to manage postsurgical pain following total knee replacement surgery. The data found EXPAREL use associated with improved clinical outcomes and a favorable cost savings per patient compared to the standard of care. The results were presented today at the 27 th annual meeting and expo of the Academy of Managed Care Pharmacy in San Diego from April 7-10.

"Our analysis found notable improvements in postoperative mobility and length of hospital stay associated with EXPAREL, which in turn resulted in meaningful reductions in cost of care," said Carl V. Asche, Ph.D., the study's co-lead and director of the Center for Outcomes Research at the University of Illinois College of Medicine in Peoria.

Dr. Carmen S. Kirkness, PT, PhD, who co-led the study, added, "While our results were specific to a single institution and surgery type, we believe our methodology could serve as a model for minimizing the biases which often confound drug utilization evaluation studies, and help other institutions accurately assess the utility of EXPAREL."

Dr. Asche and colleagues compared two matched cohorts of 134 patients who received either an EXPAREL-based regimen or the standard of care (continuous nerve block with ropivacaine and/or local infiltration with varying combinations of ketorolac, ropivacaine, epinephrine and morphine sulfate).

Key findings associated with the use of EXPAREL included:
  • Shorter length of hospital stay (2.8 ± 1.7 days for the EXPAREL group vs. 3.2 ± 1.6 days for the control group, P<0.05)
    • 50% of patients in the EXPAREL group vs. 19% in the control group were discharged ≤2 days after surgery (P<0.001)
  • Greater mobility after surgery - measured by mean distance walked - (19.8 feet for the EXPAREL group vs. 10.3 feet for the control group on the day of surgery; P<0.01; and 209.1 feet for the EXPAREL group vs. 83.7 feet for the control group, on first day after surgery; P<0.05)
  • Savings of $366 per patient on direct hospital costs ($8,816 ± $1,717 for the EXPAREL group vs. $9,182 ± $2,031 for the control group; P>0.05)

"The results from the University of Illinois study further reinforce the health economic impact of EXPAREL, which, coupled with its measurable improvement to patient care, are integral to gaining institution-wide adoption and being accepted as the new standard of care in postsurgical pain management," added Dave Stack, president, chief executive officer, chairman and director of Pacira.

EXPAREL is currently indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam ®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain score with up to a 45 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting. Please see the full Prescribing Information for more details available at

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's flagship product, EXPAREL ® (bupivacaine liposome injectable suspension), a non-opioid local analgesic for postsurgical pain control, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam ®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at

Forward Looking Statements

Any statements in this press release about our future expectations, plans, outlook and prospects, including statements about our expected revenues, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our plans to expand the use of EXPAREL to additional indications, including nerve block, oral surgery and chronic pain, as well as pediatrics; the related timing and success of a United States Food and Drug Administration supplemental New Drug Application; our receipt of FDA approval of our nerve block indication; the adverse effects and impacts of FDA warning letters; our plans to evaluate, develop and pursue additional DepoFoam-based product candidates; clinical studies in support of an existing or potential DepoFoam-based product; our plans to continue to manufacture and provide support services for our commercial partners who have licensed DepoCyt(e); our commercialization and marketing capabilities; our and Patheon UK Limited's ability to successfully and timely construct dedicated EXPAREL manufacturing suites; and other factors discussed in the "Risk Factors" of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Copyright Business Wire 2010